Patient diversity and developing drug resistance can undermine the efficiency of existing therapies in a long-term pharmacological treatment of diseases, such as cancer and infections.
One of the promising strategies, in this case, is applying multicomponent therapeutics, leading the way to more personalized medicine. Approved drugs appear to be the ideal starting point for the development of novel multidrug treatments enjoying a fast track to new clinical applications.
Indeed, they are already known to be safe, effective and bioavailable. Last, but not least, they usually have well-defined targets and mechanisms of action.
Another important strategy in modern pharmaceutical research is drug repurposing. Drugs which once failed as effective treatments for one disease might well become “blockbuster” cures for another.